Humacyte, Inc. (HUMA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.60+1.49%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · HUMA
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | 2.1 | 2.0 | — | — | — | — | — |
| Cost of Revenues | 12.6 | 9.7 | — | — | — | — | — |
| Operating Expenses & Income | |||||||
| R&D Expenses | 69.5 | 69.3 | 88.6 | 76.6 | 63.3 | 61.3 | 54.1 |
| Operating Income | (111.2) | (108.1) | (114.4) | (100.0) | (84.6) | (81.2) | (64.6) |
| Earnings from Continuing Operations | |||||||
| Interest Expense | — | 11.3 | 9.3 | 6.6 | 6.2 | 4.3 | 2.2 |
| Interest & Investment Income | 1.8 | 2.6 | 4.1 | 5.5 | 2.6 | 0.0 | 0.3 |
| Net Interest Expenses | — | — | — | 1.1 | 3.6 | 4.3 | 1.9 |
| Other Non-Operating Income / Expenses | 14.4 | 67.3 | (34.3) | (10.7) | 72.6 | 54.7 | (1.9) |
| EBT, Incl. Unusual Items | — | (40.8) | — | — | — | — | — |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | |||||||
| Net Income | (96.7) | (40.8) | (148.7) | (110.8) | (12.0) | (26.5) | (66.5) |
| Per Share | |||||||
| Basic EPS | (0.41) | (0.26) | (1.26) | (1.07) | (0.12) | (0.66) | (11.54) |
| Diluted EPS | (0.41) | (0.26) | (1.26) | (1.07) | (0.12) | (0.66) | (11.54) |
| Revenue per Share | 0.01 | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 234.2 | 158.2 | 118.5 | 103.4 | 103.1 | 40.0 | 5.8 |
| Diluted Weighted Avg Shares | 234.2 | 158.2 | 118.5 | 103.4 | 103.1 | 40.0 | 5.8 |
| Supplemental | |||||||
| EBIT | (111.2) | (108.1) | (114.4) | (100.0) | (84.6) | (81.2) | (64.6) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.